期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 16, 期 7, 页码 815-830出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1182021
关键词
Parkinson's disease; genetic polymorphism; pharmacogenetics; individualized medicine; personalized medicine; precision medicine
资金
- Korea Health technology RAMP
- D Project, Ministry of Health AMP
- Welfare, Republic of Korea [A101273]
Introduction: There is a considerable inter-individual heterogeneity in clinical features, disease course, and treatment response in Parkinson's disease (PD), which can be explained not only by disease process and clinical variables, but also by an impact from genetic factors. Evidence-based medicine relies on large randomized control trials and meta-analysis-average medicine, which ignores individual differences. However, we are now in the early phases of a paradigm shift in medicine relating to individuality and variability. The purpose of individualized medicine is to predict patients' responses to targeted therapy using diagnostic tests based on genetics or other molecular mechanisms, thus providing the right drug at the right dose at the right time. Areas covered: In this article, we outline current state of individualized medicine for PD. Expert Commentary: Pharmacogenomics, an important element of individualized medicine, is just beginning to be considered in PD. To advance the clinical use of pharmacogenomics, big data cohort for genomic research and multidisciplinary team approaches are necessary.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据